<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204321</url>
  </required_header>
  <id_info>
    <org_study_id>Hausberg_Lang-Sir/MMF</org_study_id>
    <secondary_id>EKF Hausberg Lang</secondary_id>
    <nct_id>NCT00204321</nct_id>
  </id_info>
  <brief_title>Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients</brief_title>
  <official_title>Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients - Positive Effects of Calcineurin-free Immunosuppression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Else Kröner Fresenius Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <brief_summary>
    <textblock>
      Chronic transplant nephropathy and cardiovascular death are the main reasons for loss of&#xD;
      transplanted organs after kidney transplantation.&#xD;
&#xD;
      Vascular changes, induced by hypertension and/or immunological processes, determine long time&#xD;
      transplant survival.&#xD;
&#xD;
      It will be tested whether the withdrawal of calcineurininhibitors will improve the vessel&#xD;
      wall function in renal transplant patients. It is supposed that this immunosuppressive&#xD;
      regimen reduces the activation of endothelial cells with important impact on arteriosclerosis&#xD;
      and therefore on patient and transplant survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiovascular complications and chronic rejection are chief causes of transplant loss[1,2].&#xD;
      After renal transplantation patients are still characterized by their pre-existing&#xD;
      arteriosclerotic changes [3]. Endothelial dysfunction and disturbed distensibility of great&#xD;
      arteries are independent predictors of cardiovascular morbidity [4,5]. Additionally the&#xD;
      activation of sympathetic nervous system leads to dysfunction of vessel wall[6,7]. There are&#xD;
      important therapeutic options in improvement of endothelial function [8].&#xD;
&#xD;
      In addition monocytes of the recipient will contribute to vessel wall changes. [9-11]. Aim of&#xD;
      therapy - especially of immunosuppressive therapy- have to prevent these fatal vessel wall&#xD;
      changes.&#xD;
&#xD;
      Therefore in this study the following topics will be addressed.&#xD;
&#xD;
      1. Discontinuing of calcineurininhibitors will lead to improvement of vessel wall function 2.&#xD;
      Sirolimus and Mycophenolat Mofetil affect vessel wall properties in a different way.&#xD;
&#xD;
      3. There are risk factors, e.g. activity of sympathetic nervous system, which may determine&#xD;
      the efficacy of discontinuing the calcineurininhibitor concerning the vessel wall function.&#xD;
&#xD;
      4. Calcineurininhibitorfree immunosuppression reduces the activity of endothelial cells.&#xD;
&#xD;
      5. Survival of monocytes and release of procoagulatory activity will be changed by the&#xD;
      immunosuppressive regimen.&#xD;
&#xD;
        1. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Cardiovascular complications in renal&#xD;
           failure. J Am Soc Nephrol. 1991; 2: 1053-1062&#xD;
&#xD;
        2. London GM, Druecke TB. Atherosclerosis and arteriosclerosis in chronic renal failure.&#xD;
           Kidney Int 1997; 51(6):1678-1695.&#xD;
&#xD;
        3. Hausberg, M., K. Kisters, M. Kosch, K. H. Rahn, and M. Barenbrock. Flow-mediated&#xD;
           vasodilation and distensibility of the brachial artery in renal allograft recipients.&#xD;
           Kidney Int. 55: 1104-1110, 1999.&#xD;
&#xD;
        4. Barenbrock M, Kosch M, Jöster E, Kisters K, Rahn KH, Hausberg M: Reduced arterial&#xD;
           distensibility is a predictor of cardiovascular disease in patients after renal&#xD;
           transplantation. Journal of Hypertension 2002, 20:79-84.&#xD;
&#xD;
        5. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FHM, Marchais SY. Forearm reactive&#xD;
           hyperemia and mortality in end-stage-disease. Kidney Int 2004, 65:700-704.&#xD;
&#xD;
        6. Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Fouad-Tarazi F, Victor RG.&#xD;
           Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;&#xD;
           327:1912-1918.&#xD;
&#xD;
        7. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH.&#xD;
           Sympathetic nerve activity in end-stage renal disease. Circulation. 2002, 106:1974-9.&#xD;
&#xD;
        8. Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship between muscle&#xD;
           sympathetic nerve activity and large artery mechanical vessel wall properties in renal&#xD;
           transplant patients. J Hypertens. 2002, 20:501-8.&#xD;
&#xD;
        9. Österud, A., Björklid E. Role of monocytes in atherogenesis. Physiological reviews,&#xD;
           2003, 83: 1069-1112.&#xD;
&#xD;
       10. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan&#xD;
           14;340(2):115-26.&#xD;
&#xD;
       11. Lessner SM, Prado HL, Waller EK, Galis ZS. Atherosclerotic lesions grow through&#xD;
           recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol.&#xD;
           2002 Jun;160(6):2145-55.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distensibility</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>sympathetic nervous system activity</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>endothelial cell marker expression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>monocyte survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Renal Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus (drug), mmf (drug)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        renal transplantation stable function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        acute rejection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Hausberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKM - Medical Department D</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UKM</name>
      <address>
        <city>Münster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>January 12, 2010</last_update_submitted>
  <last_update_submitted_qc>January 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Hausberg</name_title>
    <organization>UKM</organization>
  </responsible_party>
  <keyword>rejection</keyword>
  <keyword>vesselwall function</keyword>
  <keyword>endothelial cell function</keyword>
  <keyword>monocytes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

